Thank you for standing by and welcome to Tandem's Fourth Quarter and Year-end 2021 Earnings Call. [Operator Instructions] I would now like to hand the conference over to your host, EVP, and Chief Administrative Officer, Susan Morrison. You may begin.

Thanks Latif. Good afternoon everyone and thank you for joining Tandem's fourth quarter and year-end 2021 earnings call. Today's discussion will include forward-looking statements. These statements reflect management's expectations about future events, product development timelines, financial performance and operating plans, and speak only as of today's date. There are risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in our forward-looking statements. A list of factors that could cause actual results to be materially different from those expressed or implied by any of these forward-looking statements is highlighted in our press release issued earlier today and under the Risk Factors portion and elsewhere in our most recent annual report on Form 10-K and our other SEC filings. We assume no obligation to publicly update any forward-looking statements whether as a result of new information, future events, or other factors. In addition, today's discussion will include references to adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is a key measure used by us to evaluate operating performance, generate future operating plans, and make strategic decisions for the allocation of capital. Please refer to our press release issued earlier today for further information. Hosting today's call are John Sheridan, our President and CEO; Brian Hansen, Executive Vice President and Chief Commercial Officer; and Leigh Vosseller, our Executive Vice President and Chief Financial Officer. Following the prepared remarks, we'll open up the call for questions. Thank you in advance for limiting yourself to one question and one follow-up before getting back into the queue. I'll now turn the call over to John.

Thank you, Susan, and welcome everyone to today's call. As you can see in today's results, the fourth quarter was a strong finish to an impressive year for Tandem. And looking back at the highlights of the year, we set record sales for both of quarter and the year. We also furthered our leadership position in markets outside the United States with an expanded international launch of our Control IQ technology. Operationally, we focused on continuous improvement throughout our business and we reached an impressive milestone of achieving our first year of positive operating margin. Finally, as we highlighted at our R&D Day late last year, we furthered our product development efforts to support our near and longer-term portfolio. In addition to these accomplishments just last week, we achieved the exciting milestone of FDA clearance of a mobile app that enables our t:slim X2 pump users to bolus insulin from their smartphones. With this clearance, we are adding to the list of Tandem firsts, as this is the first-ever FDA-cleared smartphone app capable of initiating insulin delivery on both iOS and Android operating systems. Organizationally, we've also been enhancing our structure over the past few quarters, with the creation of new senior leadership positions. We welcome talented and experienced individuals who complement and strengthen our management team as we scale the business and prepare for continued growth, near-term product launches, and the execution of our longer-term strategy. It's an important step as Tandem has a great opportunity to further our market-leading position in Diabetes Care. Our installed base has nearly quadrupled in the past three years, which is evidence that our innovations drive adoption. I am proud that nearly 330,000 people worldwide use a t:slim X2 for their therapeutic management. Credit for these achievements goes to our talented employees. We…

Thanks, John. What stands out for me is that our t:slim X2 platform continues to be the leading insulin therapy solution for the durable pump community, which is the largest segment of the insulin pump market. In fact, recent U.S. data suggests that more people chose the t:slim X2 last year compared to any other pump offerings and that the market is continuing to accelerate. We estimate that more than 70,000 people in the United States adopted insulin pump therapy for multiple daily injections in 2021 which is double the number of people who adopted pump therapy just three years ago. Outside the United States, we see a similar trend that suggests the pump therapy penetration is also accelerating. With this market growth, I am proud that Tandem continues to make meaningful progress in our long-standing goal to bring the benefits of pump therapy to more people with diabetes. In the fourth quarter, we once again saw a balanced source of new customer growth in the United States, with approximately half of our customers reporting that they've converted from another pump manufacturer and half from multiple daily injections. We're also gaining increased visibility into our growth sources outside the United States where we see both the high number of competitive conversions and people new to pump therapy. It's a testament to the ease of use and form factor of our platform, its software updatability from a home computer, the proven performance of our Control IQ technology and the customer experience we provide. In January, we held a virtual national sales meeting, which was great timing as a sales force expansion from 95 territories to 110 territories is now complete. At the meeting, we heard high enthusiasm for our t:slim X2 pump and strong conviction in our Control IQ technology. The…

Thank you, Brian. At our R&D Day event in December, we shared our longer-term vision and strategy for driving continued growth through innovation. It's rooted in a foundation of extensive market research, which is a practice that we began at the Company's inception. A consistent outcome from these results has been that there is no one size fits all solution in diabetes management. How a person chooses to wear their pump is a big driver in their purchasing decision and it's based on personal needs and preferences. As a result, this creates segments in both the Type 1 and Type 2 markets and our portfolio approach is designed to bring new solutions to more people living with diabetes. We are continuing to invest in advancing our t:slim platform along with bringing our miniaturized durable pump to market as well as tubeless options. From a timing perspective, the next new pump we intend to launch is a Tandem Mobi which we historically referred to under its development named t:sport. Mobi gives us an opportunity to serve a new market segment with an even smaller, more discrete pump using leading-edge hardware technology. We chose the name Mobi to represent the pumps mobility in the way it's warrant and is a nod to its mobile app-based interface. The Mobi pump is designed to be fully controlled through a mobile app on a user's personal smartphone. The t:connect mobile app that was cleared last week for bolus insulin delivery is also the foundation of Mobi's mobile control functionality. Last year during the regulatory review for our mobile bolus feature for the t:slim X2 platform, we were able to get clarity on the FDA's expectation for pump mobile control functionality and all that learning has been applied to the Mobi full control mobile app development…

Thank you, John, and good afternoon everyone. The 2021 was another record-breaking sales performance for us as we scale from just under $500 million sales in 2020 to more than $700 million in 2021. This represents 41% growth over 2020, which we successfully delivered despite the unique and unpredictable challenges of the pandemic. We shipped nearly 130,000 pumps worldwide, of which approximately 30% were shipped in the fourth quarter alone. This brings us to our worldwide installed base of nearly 330,000 customers. Fourth quarter worldwide sales were a record $210 million, which is a point of comparison as meaningfully more than our full-year sales in 2018. This is a significant achievement in only a three-year timeframe. Specific to the U.S. market, 2021 sales grew 26% to $525 million. More than half of our sales were driven by shipment of approximately 83,000 pumps in the year. Our U.S. installed base of nearly 240,000 customers also drove meaningful growth in our supply sales and builds the foundation for pump renewal sales in the future. Following on Brian's remarks regarding our renewal progress, we reached our goal to renew approximately 60% of the more than 65,000 pump warranties that cumulatively expired at the end of 2021. While the majority of the renewals this year were generated from 2021 warranty explorations, there were still a meaningful contributions from warranty explorations as far back as 2016 and we expect continued renewal sales in the future from warranties that expired in years past. As we look at our 2022 renewal opportunity, approximately 30,000 additional customers will become eligible for renewal based on our 2018 shipments. Importantly, more than 40% of these customers will not be eligible for renewal until their warranties expire in the fourth quarter at 2022 which will influence the timing of those renewal…

[Operator Instructions] Our first question comes from the line of Chris Pasquale of Guggenheim. Your line is open.

Thanks and congrats on a nice finish to a strong year. Wanted to just drill in on the renewal opportunity something that should be a big driver for you guys over the next couple of years. It would be great to just get an absolute number for what you think the renewals were in 2021. You gave a lot of details around rates, but it'd be great to have a baseline there.

Sure. Thanks for the compliment, Chris. I'm happy to talk to you today. So with regards to renewals, first of all I'd say that yes, it's becoming a growing opportunity, which will be much more meaningful in the coming years. For 2021 and even again for 2022, the vast majority of our pump sales will still come from pumpers new to Tandem. And we have made great progress though and it's not that we are renewing people, it's just that the opportunity volume hasn't grown as much. So in 2022, it's going to increase by about 30,000 new opportunities, which is where we'll really start to see more contribution, but it's pretty back half-loaded, so we can think about is more of a 2022 and into 2023 opportunity and just to give you maybe a little more perspective on that breakdown, you can think of the new pumpers are still being more than 80% of what we shipped in 2021.

Okay, that's helpful, thanks. And then on margins, flat gross margin, '22 versus '21, maybe not too surprising given some of the cost pressures the industry is dealing with broadly, but it was good to hear you reiterate the long-term goal. Just curious on the drivers there, how much of it is dependent on new products? How much of it is dependent on reimbursement, which is little bit out of your control as you think about getting the 65 long-term?

Sure. So when you think about it, I usually put it in three buckets. What you've been seeing that's demonstrated is really the incremental benefits each year as we grow our volumes, leverage our overhead, and just keep identifying cost-saving initiatives and efficiencies within the processes themselves, the real step changes will come when we launch new products. So for example with Mobi coming once we get to a level of scale, we've estimated that that product cost should be about 20% better than the t-slim itself. So you can see that's where you will start to see step changes going towards that 65% long-term goal. The reimbursement initiatives are more similar to incremental progress like we're seeing on the volume side, it's really about continued conversations with the insurance payers, getting more direct contracts, and looking for price increases as we move along, especially as we're using our clinical data to share the benefits that their patients are seeing. So you can think about it within those three ways.

Our next question comes from Brooks O'Neil of Lake Street Capital. Your line is open.

Thank you and good afternoon and congratulations on the terrific finish to 2021. I'm just curiously, if you could talk a little bit about the assumptions you include in the 2022 guidance. John mentioned I think two CGM partners, both Dexcom and Abbott, and I'm curious how you think about the impact of G7 and Libre 3? And then whether you've included in assumption about contribution from Mobi in the 2022 guidance? Thanks a lot.

Okay. Thank you, Brooks. So in terms of guidance, just our overall philosophy as we typically do not include products not yet approved in any of our guidance level, so to answer your questions on CGM as well as Mobi, those would not be factored into our 2022 guidance at this point. What has been included though is the continued enthusiasm for Control IQ. It still has not yet reached its full market potential even here in the U.S. where it's been around now for two years, but especially outside the U.S. where we're just starting to roll it out in France and Germany in just the recent months. And so we still think we have a great runway with Control IQ and now with the addition of mobile bolus, it gives us a lot to talk about with our customers.

Our next question comes from Larry Biegelsen of Wells Fargo. Your line is open.

Hi, this is Nathan on for Larry. Just a question sticking to 2022 guidance. What are you assuming for competition we just saw Omnipod 5 approval, we also have Medtronic's warning letter and potential impact to their pump? So what to assume that in your guidance?

Sure. And thanks for the question. So when we think about what's included, I already mentioned Control IQ, but in particular we still think we're going to continue penetrating the MDI population and see growth in competitive conversions year-over-year. As we think about competition this year, we really factored in I would say more at the noise level. If you think about it, we're still the leading pump player in the durable pump segment, which is the largest of the segment. I mean, we don't see a lot of switching back and forth between tubed and tubeless pumps and so at this point, we are contouring at noise level like we have seen in the past where new products are launched and sometimes that causes a little bit of near-term disruption.

Okay, that's helpful and then you previously indicated the plan on beginning the Type 2 Control IQ pivotal study in '22. Can you provide an update on timing? What do you think you would need to show in the study to achieve traction inside two? And also, when would you expect the Type 2 label and how important is this to you?

Thanks, David. Well, right now we're enrolling our Type 2 feasibility study, and this is something that we work with the FDA on to just understand the various segments of the Type 2 community and just to test them out in a smaller study. It turns out that sometimes, I would say that probably late next year or early 2023 we would initiate our Type 2 feat - our pivotal study. It's going to be a large study. And I think that's roughly what we would expect for timing. So I think we're looking at it indication probably in the 2023 timeframe.

Our next question comes from Alex Nowak of Craig-Hallum Capital. Your line is open.

Great. Good afternoon, everyone. With several diabetes approvals making their way to the FDA in the last couple of weeks, are you starting to see the backlog at that agency start to ease a bit here? And then when you take the learnings from mobile bolus, you document those and then you fold them into Mobi, how are you thinking about what you need to change to Mobi additional studies that might be needed on the bench side? And then how are you thinking about timing for approval there?

Yes. Good questions, Alex. I would say it's difficult to say still as to whether or not the FDA has got additional resources that have come back from just supporting the COVID work that they are involved in. So I think as we have to wait and see still. I would say that they've been very supportive with the limited staff and we're very happy to appreciative to get the approval, but it's still early in my mind that I think we need another quarter or two to see if in fact things do change there. When it comes to Mobi, I would say that we have - we learned a great deal. There was not a lot of new information that came as they did approve the device, which was good and so I would say that right now essentially we've incorporated the learnings from the questions that we received last year into Mobi at this point in time. And we've really transitioned from a development mode into more of a testing mode. As I indicated, we're involved right now in the largest some of the study that we've done for human factors testing, we did at least 15 - at least maybe 15 or 17 formula studies, leading up to it. So there's a great deal of experience that we're comfortable with the results, but it's a very complex study. It's going to take several months. It's going to be involved - multiple cities will be involved, multiple types of segments within the diabetes community will be involved. So it's a long and extensive study. And so that's really, we have to finish that. There are also additional verification validation studies and test things that we have to do inside the company. So I think that puts us to a summertime submission and we feel good about that.

And then with outside the U.S. just becoming much more important to the company here, can you just give us an update on where you stand today as far as your pump versus the installed base of pumps out there, the share of new pumps being placed outside the U.S. market? And then just how as Medtronic 780G launch there changed the sales process for you?

So I'll start with a little bit on just the color of where we stand today. If I understand your question correctly, please correct me if I'm wrong here, when you think about where our business is coming from, it's much like the U.S. where there is a high level of competitor conversions coming our way as well as people new to MDI. So we continue to penetrate those markets and we're especially excited about Control IQ and the great demand that we're seeing and interest in that product as we look forward. And then if Brian will talk a little bit about the selling environment as it relates to 780G out there today.

Yes, I think as we see here in the U.S. we see the power of Control IQ in our international markets as well. And we really haven't seen a dramatic influence or shift from that product in the market, so we compete against it today. So we feel pretty good about it. We certainly have a lot of visibility with our partners. We have great relationships without partners. We have balanced growth across all the regions we're in right now. So the early indications are Control IQ is doing very, very well.

Our next question comes from Steve Lichtman of Oppenheimer and Company. Your line is open.

You saw solid 4Q, so obviously able to overcome COVID headwinds. I was wondering what kind of impact you did see from COVID in the quarter and what you're seeing as the year turned, and as you mentioned, John, COVID cases have started to come down?

I'll take that one, this is Brian. It was an interesting year for sure. And I think the best thing we probably say is we remain cautious because we've kind of been here before. I said in my earlier statements, very proud of the team and the work they've done over the last two years and in Q3, we saw things kind of open up, but it was characterized by almost an extended holiday or vacation period. And as we moved into Q4, we have a lot of optimism. The new variant came and it began to change access for us to our patients and our healthcare providers. We first saw in Europe and then we saw here in North America. So we kind of migrated back towards our remote model in many regions and think we were pretty good at that. The difference in Q4 was we saw a lot of COVID-19 positives at that point. We saw with their health care providers, we saw with some of our patients and we saw internally here with our staff internal and external, and our partners. So it was just an odd quarter to kind of navigate through. We did so successfully. We certainly hope that it moderates now and we head into some clear waters in 2022, but again we are cautious -

I think there is still uncertainty as we move into this year and we'll start to keep our eye on it.

And then also on the commercial organization, what kind of tailwind could you expand in sales force providing '22 you're not having nice growth in the commercial team? Is it getting you into new regions you weren't in before or more about going deeper? And will we see a material benefit from the expansion '22 or is that more meaningful in '23?

Well, I'll start with the purpose behind it. One was to reduce some of the workload on our existing staff because they were simply getting a lot of patients to handle in their current territories. So going from 95 to 110 was to ease a little bit of that burden, but then that allows us to do exactly what you said, go a little deeper in our existing accounts and also get out see some additional accounts that we may not spend as much time with, so we opportunistically look for those areas where we were just getting a little bit too large. we may not be doing all that we could be doing in that areas. This allowed us to right-size the sales side and the clinical side a little bit and yes, I do think it's certainly going to provide some benefit for us this year and our folks are very happy to get that release. Leigh, if you want to talk any further to that.

No. That's great.

Our next question comes from Matthew O'Brien of Piper Sandler. Please go ahead.

Good afternoon, and thanks for taking the question. So just to put a little bit finer point on the potential tailwind on the Medtronic side of things, I think they said $200 million to $300 million is the impact they expect this year. Just using the midpoint of that, 250, I think around half of that is insulin pumps and supplies and I'm assuming majority of those folks are into durable pumps. So as I look, Leigh, at the domestic guidance, it looks like you're only factoring in, I don't know, somewhere in the $10 million to $20 million range from that tailwind. Are those numbers kind of ballpark? And then I guess why be still conservative with the potential tailwind on the Medtronic side?

So, thanks for the question, Matt. So, we haven't actually quantified obviously how much we're thinking about it, but I guess one point to make is we were coming into this year, I think many people thought that our competitive conversion opportunity was going to go down where in fact we still expect that it will increase this year and maintain that same healthy balance of new pumpers coming from MDI and competitive conversions. So, we still think the opportunity is strong but as is our nature and that we're continuing to navigate the COVID environment, we're going to be cautious initially until we see continued trends that might suggest otherwise.

Okay. So, there are some conservatism built-in based on what you've seen from Medtronic so far?

That's correct.

Okay, thank you. And then on the competitive side, the Control IQ momentum that you have is a Form Factor enough to really dislodge a bunch of existing patients or even new to pumping patients heading into the full launch of [indiscernible] or do you need to see real-world data for a year of kind of post full approval or is the momentum so strong with CIQ that it's really going to be difficult to slow things down from a momentum perspective in terms of what you've got going? Thanks.

I'd say briefly we're really comfortable with our position and certainly where we sit right now the competitive messaging that's out there is it's early to tell. We certainly haven't seen a reduction in our pipeline and in these phase rollouts. We will surely learn more over the coming periods here, but Control IQ and the outcomes that we've seen, Control IQ continued to be a real positive for us. Launching mobile bolus is an exciting opportunity for us to get in to visit our accounts. The product pipeline certainly leads to great things at the end of the year and next year and then the services we provide, our infrastructure we have in place, I think puts us in a really good spot.

And Matt I just to add to that the, when you look at the algorithms themselves and you look at the results, there's really - there's not a whole lot of significant differentiation, I would say that it's some convergence of anything. And if there is more to it, we really do believe Form Factor is important. And when you look at our pipeline, we've got Control IQ and t:slim doing very well today. We've got Mobi filing here shortly. We've got additional sensor partnership integrations, which I think are really going to give us a sales boost as well with this new technology. And then we've got X3, we've got Mobi tubeless, we've got patch here in the next three to five years. So I think that we feel very well positioned to compete and as Brian said, there's not a lot of information out there right now, we're going to have to wait and see what happens. But we feel very, in a very strong position to compete with the other element - other players in this market.

Our next question comes from Matt Taylor of UBS. Your line is open.

So, I did want to ask one follow-up on you mentioned that you're baking in some conservatism to the international guidance, maybe just talk about what you're seeing how conservative you're being? And what's the FX number that we should be using for international?

Sure. Hey, Matt. So I'm actually - and let Brian talk about the environment a little bit because I think that helps explain better the caution that we're putting into the guidance. But I'll take the simplest one first which is we have very little FX exposure. So nothing to speak to in terms of from a materiality perspective.

Okay. Thank you.

We have great relationships with our partners. We have great visibility to the work that they're doing and again, we talked about the balance of just growth across all of our regions. It was an interesting end to the year, as we prepared to launch Control IQ in Q3 and into Q4, especially in our newest geographies, we encountered several factors that made it quite complex. One was the unknown demand. These were large markets that we were going into, specifically France and Germany. They're newer partners for us. There is different distribution models in those countries, which makes it even more complex and one of the reasons, they were a little bit later in our launch cadence and there were some really unique supply chain issues that hit us in Q4, whether it was by air or by sea. It was hard to get things out the door and on schedule over there. So there's plenty to learn from Q4. The good news is the demand for Control IQ continues and the variability that we're experiencing should take care of itself as we move into the middle part of the year and as we talked about, the competitive environment remains fairly strong in our position right now. So I remain pretty bullish on what we're doing.

Our next question comes from Danielle Antalffy of SVB Leerink. Please go ahead.

So congrats on a strong end to the year. And just a question on where we are with penetration today. Leigh, I think you've mentioned that something like double the number of new patients started on pump therapy this year versus three years ago. How are you feeling about your long-term sort of target out there for pump penetration in Type 1 based on where we exited the year? And then one follow-up on international.

Danielle, I'll go ahead and take that, I mean I think we feel very positive about in continued pump penetration and it's not just being driven by Tandem, but when you look at the diabetes med tech community in general, there's been a tremendous amount of innovation that's occurred over the last couple of years and there is more innovation coming and I think that it's all intended to just reduce the burden of diabetes and we believe that ease-of-use drives adoption. We've stated specifically that we think we can get to 60% to 65% penetration and when you look at our pipeline, we think we've got innovation that's going to continue to drive that as well as our partners and competitors. So we think it's a number that it's going to continue to expand. And as you said, we've seen aggressive growth in MDI penetration in the last couple of years, we expect to see it continue to happen, and not only in the U.S. markets, but also OUS as we bring this technology to Europe and other countries that we're in today. We think it's going to happen there as well.

Well, you've swept through on my question, John. My next question was going to be in the - some of these major international market where - what the incremental maybe, that's a better way to think about it, incremental runway for penetration is versus where we are today? And what's going to drive - what are going to be in the markets to drive you over the next few years internationally?

I think the factors are the same. The same factors that are affecting pump penetration improvements in the U.S. are going to occur OUS. And I would say right now, our numbers would suggest that the pump penetration in the markets we're in today is approximately 5% to 10% and we think that can probably double, maybe more than double in the next three to five years, and that's also with a much larger market, as you know, in the States, it's a approximately 1.7 million or 1.8 million people with diabetes, in the markets we're in today is 4 million. And so as we make improvements in the pump penetration there, it's a much bigger number for all of us to participate in.

Our next question comes from Jayson Bedford of Raymond James. Your line is open.

I have a few questions here. So maybe for Brian, you mentioned over 70,000 folks adopted pump therapy in 2021. Just embedded in the guidance, what's the expectation for that number in 2022?

I think we haven't given a specific number other than we think that our ability to penetrate the MDI population will continue to increase in 2022. So the drivers that have made us successful so far are still there. It's more MDI patients coming our way, it's more competitor conversions, and it's an increase in the number of renewals that will ship this year.

Okay. I guess just on the renewals, you mentioned an incremental 30,000 coming due I think in 2022. Can you just update us on the actual number of renewals either exiting '21 or '22 we can back into one of the years, but what's the actual number of renewals out there?

Sure. What we actually achieved by the end of 2021, there is more than 65,000 people whose warranties have expired over the years since the beginning and we have renewed a significant portion of those. And so what we're looking at as we go forward, I think one of the things that to think about is the information we gave today on where we exited 2021 which is that nearly half of the people whose warranties expired in 2021 have already renewed. So you can think about that as you look forward into 2022 and what that additional 30,000 opportunities might provide for us and 2021 is not done and 2020 is not done, there's still people coming from way back that will continue to be renewal opportunities as we look forward.

Okay. So I had a number about 60,000 exiting '22. Is that in the ballpark for cumulative renewals?

Oh, sorry, I don't think I - yes, I don't think I gave you that specific metric. Of the more than 65,000 customers, 60,000 have renewed by the end of 2021. I mean, sorry, 60% of them. Sorry.

It was, say wow.

I know.

Okay. Okay, that's helpful and then just in terms of mobile bolus in Europe, can you just talk about where you are, your thought there and then maybe some of the challenges of introducing such technology in Europe where I think they have stricter laws around privacy?

Yes, great question. When you look at the results that you can see about quarter of our revenue came from OUS. And I think that we've quickly become an international company. I think that we need to have structured our product pipeline so that also represents and provides this technology and innovation to the OUS countries. So we're absolutely committed to providing mobile bolus and Mobi and all of our products OUS is something that we have to do. I think you're right, there is some complexity. But right now, as we've talked about in the past, we are rolling out Tandem Source. Right now, it's in the UK in a, I guess, early release state and the intent of Tandem Source would be to integrate with mobile technology and so it's definitely something that we have in the roadmap. We just haven't been very clear yet intentionally about what the timing is, but I think that will come in time.

And so mobile bolus in Europe is more of a '23 dynamic than '22, is that fair?

I mean that's a fair thing to say. Yes, we haven't been clear - that clear about it, but I think it's fair.

Our next question comes from Jeff Johnson of Baird. Your line is open.

Thank you. Good afternoon, guys. John, maybe one clarifying question for you and then one pump volume question, modeling question for Leigh, but on the clarifying side, you talked about ACE pump submission for Mobi maybe in middle of the mid-summer or summer of this year. I think you said.

Yes.

Is there anything within ACE pump submission that would think - that would make us think that it's more than kind of a typical or less than a typical six-month 510(k) review pathway? I mean, I know COVID has created uncertainty around review timelines, but historically we think a 510(k)s is about a six-month. So, is that fair with the Mobi submission or maybe a late '22 or early '23 kind of potential approval timeline is a way to think about it?

I think that's very fair prior to COVID occurring, but right now, I think that it's still - I think the jury is still out as to how much additional resources Diabetes Group at the FDA get in the next couple of months. We hope that things return to normal by that time because we'd of course like to get the product on the market as quickly as possible, but I think there's this inherent uncertainty in their resource and staffing levels at this point in time, but we're going to have to wait a little bit more time just to see how it plays out.

Okay, so ex-FDA assumptions in ACE pump kind of that typical six-month is fair, is it that way to think about it?

Yes.

Okay. Yes, perfect. And then, Leigh, just from a pump volume standpoint, I know you don't guide to pump volumes, but I'm going to ask a question around that anyway. You know, when I look at your U.S. pump volumes in the first half of this year of '21, they grew over 30% in the second half, I think they were up upper single digits. Is your guidance for '22 kind of implying somewhere in between there comps ease, hopefully COVID falls off a little bit, so maybe pump volumes in the U.S. grow somewhere between the second half and the first half of '21, is that a reasonable guesstimate for the year?

Yes, you know, I think it's challenging to take the growth rates in 2021 and apply any sense of normalcy to it. If you think about really what was happening in the base year of 2020, COVID had the most significant impact in the first half of that year and in the back half, what we were starting to see was we were actually starting to feel optimistic at that point and it seems like things are getting back to normal and maybe a little bit of that pent-up demand from the first half of the year was coming through. So that's why the growth rates in 2021 probably are maybe a little bit unfair, but thinking of somewhere in the middle, I think makes sense for this year. We look at it as more the terms of the seasonality curve and where you come off of that launching point with pump shipments in the U.S., usually being in the high-teens as a percent of the year and in the fourth quarter, just kind of depending on - might vary in years we had product launches, but anywhere in that 30-plus percent range.

Our next question comes from Josh Jennings of Cowen and Company. Your line is open.

This is Brian in for Josh. Thank you for taking my questions. I have two longer term ones on the tubeless opportunity that's in the pipeline. First, competitor today revealed its intent to commercialize patch pumps since this comes after the R&D Day. Does that in any way change your views on Tandem's eventual opportunity in the patch market segment?

Not at all. In fact, I think we were aware of the investment that they had made in the company in the past and it's not surprising that they're considering doing this. Yes, so it's not a surprise. It doesn't change our own decisions and our strategy of moving forward with products that support both tubed and tubeless segments.

Okay, thank you. And my follow-up is just generally speaking, can the U.S. regulatory success you're accruing for two pumps be leveraged to streamline the FDA process for the development of a patch pump or are those two very distinct rounds for the agency, two pumps and patch pumps - so I'm thinking about...

Yes, yes I think that...

Yes, I was going to say I'm thinking about factors like the size of a pivotal trial or are we just too far out to know the exact scope of work there?

Well, I would say that when it comes to actually working with the FDA and its filings, we have a great deal of experience with it. We've been doing it now for many years and we understand the types of data and the depth of the analysis that we need to provide. So I think our team is very experienced when it comes to these sorts of filings. I'll also say that the entire initiative of interoperability benefits us, and I don't think that they have distinguished whether or not it's a tubed or a tubeless pump when interoperability comes to play because one of our competitors does have the ACE pump designation for a patch pump. So I think that the regulatory landscape is not going to impact us one way or the other. We just have to continue to produce well thought-out analysis and justifications for the technology. And if we do that, I think we will continue to be successful.

And ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.